Polaryx Therapeutics (PLYX) Payables (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Payables for 3 consecutive years, with $683000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables changed N/A year-over-year to $683000.0 in Q2 2026; TTM through Jun 2026 was $683000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $470000.0, up 552.78% from the prior year.
• Payables was $683000.0 for Q2 2026 at Polaryx Therapeutics, down from $850000.0 in the prior quarter.
• Over five years, Payables peaked at $850000.0 in Q1 2026 and troughed at $72000.0 in Q4 2024.
• A 3-year average of $518750.0 and a median of $576500.0 in 2025 frame the typical range for Payables.
• The widest YoY moves for Payables: up 552.78% in 2025, down 552.78% in 2025.
• Over 3 years, Payables stood at $72000.0 in 2024, then soared by 552.78% to $470000.0 in 2025, then surged by 45.32% to $683000.0 in 2026.
• The last three Payables figures came in at $683000.0 (Q2 2026), $850000.0 (Q1 2026), and $470000.0 (Q4 2025), per Business Quant data.